Matthew R Rosebraugh (Matthew Rosebraugh)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 6

Top Topics

Monoclonal Antibody

Parkinson Disease

High Resolution Mass Spectrometry

Top Venues

Pharmacology research & perspectives

Annals of neurology

This page only lists publications with an associated author ORCID identifier.

Publications

John P Savaryn, Richard L Smith, Matthew R Rosebraugh, Melina Neenan, Richard Burton, Kennan Marsh, David S Wagner
Metabolite profiling of foslevodopa/foscarbidopa in plasma of healthy human participants by LC-HRMS indicates no major differences compared to administration of levodopa/carbidopa intestinal gel. Pharmacology research & perspectives 12 (2) (2024)
John P Savaryn, Richard L Smith, Matthew R Rosebraugh, Melina Neenan, Richard Burton, Kennan Marsh, David S Wagner
Metabolite profiling of foslevodopa/foscarbidopa in plasma of healthy human participants by LC-HRMS indicates no major differences compared to administration of levodopa/carbidopa intestinal gel. Pharmacology research & perspectives 12 (2) (2024)
John P Savaryn, Richard L Smith, Matthew R Rosebraugh, Melina Neenan, Richard Burton, Kennan Marsh, David S Wagner
Metabolite profiling of foslevodopa/foscarbidopa in plasma of healthy human participants by LC-HRMS indicates no major differences compared to administration of levodopa/carbidopa intestinal gel. Pharmacology research & perspectives 12 (2) (2024)
Hari Varun Kalluri, Matthew R Rosebraugh, Thomas P Misko, Adam Ziemann, Wei Liu, Bruce Anthony Campbell Cree
Phase 1 Evaluation of Elezanumab (Anti-Repulsive Guidance Molecule A Monoclonal Antibody) in Healthy and Multiple Sclerosis Participants. Annals of neurology (2022)
Matthew R Rosebraugh, Eric A Voight, Ehab M Moussa, Feroz Jameel, Xiaochun Lou, Geoff G Z Zhang, Peter T Mayer, Deanne Stolarik, Robert A Carr, Brian P Enright, Wei Liu, Maurizio F Facheris, Philip R Kym
Foslevodopa/Foscarbidopa: A New Subcutaneous Treatment for Parkinson's Disease. Annals of neurology 90 (1) (2021)
Matthew R Rosebraugh, Hari V Kalluri, Wei Liu, Charles Locke, Dilraj Sidhu, Jian-Hwa Han, Janet Benesh
Levodopa-carbidopa intestinal gel high concentration formulation is clinically bioequivalent to commercial formulation. Pharmacology research & perspectives 7 (2) (2020)